Company Executives Offer "Crystal Ball" Predictions
Experts Discuss Need for New Approaches in Anti-Infectives
EMERYVILLE, CALIF., November 20 /CNW/ - Two NovaBay Pharmaceuticals, Inc.
(AMEX & TSX: NBY)(http://www.novabaypharma.com) executives, Chairman and CEO
Ron Najafi, Ph.D., and VP of Research, Nafsika Georgopapadakou, Ph.D., shared
their expert opinions in PharmaVOICE's "Crystal Ball" feature in the
magazine's November/December issue.
Dr. Georgopapadakou highlighted "Five Anti-Infective Trends" that will
impact the pharmaceutical industry for the next fives years, including:
-- Increased Frequency of Microbial Multi-Resistance to Commonly Used
According to Dr. Georgopapadakou, this is already happening with
multi-resistant Methicillin-resistant Staphylococcus aureus (MRSA). Dr.
Georgopapadakou says that this increased frequency is also increasing with
antivirals, such as antiretrovirals for HIV.
-- Rapid Dissemination of "Exotic," Often Opportunistic, Pathogens
Dr. Georgopapadakou reports that we are already seeing outbreaks of
Clostridium difficile, A. baumannii, West Nile Virus (WNV), and Chikungunya
virus. For many of these diseases, there is no effective treatment, and
nothing in sight.
-- Continued Paucity of New Antibiotic Classes
According to Dr. Georgopapadakou, this continued paucity might have
precipitated the exit of big pharma from infectious disease drug development.
Biotech has proved unable to produce new antibiotic classes that are not
subject to cross-resistance.
-- Increased Emphasis on Infection Control and Prophylaxis
Dr. Georgopapadakou cites the finding that almost one hundred thousand
patients die of healthcare-associated infections in the U.S. each year.
Because of this there is an increasing emphasis on rigorous control measures.
Dr. Georgopapadakou predicts that the wide use of invasive procedures and
devices is likely to give prophylaxis equal footing to therapy.
-- Emergence of Topical, Non-Antibiotic Anti-Infectives
According to Dr. Georgopapadakou, the trend toward topical
anti-infectives for vulnerable sites (eyes, nose, sinuses, ears, urinary
bladder, surgical sites, central venues catheter sites) is already happening.
This trend is fueled by the realization that extensive use of antibiotics
erodes their effectiveness and increases resistance.
Dr. Najafi spoke of what he deemed, "The Edge of the Precipice," in which
it is only a matter of time before the world is faced with a runaway pandemic.
Because the pressure of multi-drug resistant infections is increasing, in
order to combat these pandemics, Dr. Najafi says, "the pharmaceutical industry
will need to develop new approaches. These new approaches should consist of
non-antibiotic antimicrobials, so as not to risk creating resistant species."
A PDF of the article of its entirety can be found here:
(Due to its length, this URL may need to be copied/pasted into your Internet
browser's address field. Remove the extra space if one exists.)
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on
developing innovative product candidates targeting the treatment or prevention
of a wide range of infections in hospital and non-hospital environments.
NovaBay has discovered and is developing a class of non-antibiotic
anti-infective compounds, which it has named Aganocide compounds, which are
based upon small molecules that are generated by white blood cells that defend
the body against invading pathogens. NovaBay believes that Aganocide compounds
could form a platform on which to create a variety of products to address
differing needs in the treatment and prevention of bacterial and viral
infections, including Methicillin-Resistant Staphylococcus aureus (MRSA).
NovaBay has entered into a licensing and research collaboration agreement with
an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear
and sinus and in contact lens solutions and a license agreement with an
affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase
product in woundcare applications.
NovaBay(TM), Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay
Pharmaceuticals, Inc. All other trademarks and trade names are the property of
their respective owners.
For more information visit the Company's website at www.novabaypharma.com
Forward Looking Statement
This release contains forward-looking statements, which are based upon
management's current expectations, assumptions, estimates, projections and
beliefs. These statements include, but are not limited to, statements
regarding the role of IRG and the development and potential benefits of, and
the market opportunities for, NovaBay's product candidates. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking statements.
Factors that might cause or contribute to such differences include, but are
not limited to, risks and uncertainties relating to difficulties or delays in
discovery, development, testing, regulatory approval, production and marketing
of the company's product candidates, unexpected adverse side effects or
inadequate therapeutic efficacy of the product candidates, the uncertainty of
patent protection for the company's intellectual property or trade secrets,
the company's ability to obtain additional financing as necessary and
unanticipated research and development and other costs. The forward-looking
statements in this release speak only as of this date, and NovaBay disclaims
any intent or obligation to revise or update publicly any forward-looking
statement except as required by law.
For further information:
For further information: The Investor Relations Group Investor
Relations: Adam Holdsworth / Rachel Colgate / Erica Ruderman 212-825-3210 or
Media Relations: Janet Vasquez / Susan Morgenbesser 212-825-3210